TY - JOUR
T1 - Vaccinations for anal squamous cancer
T2 - Current and emerging therapies
AU - Berry, John
AU - Glasgow, Sean C.
N1 - Publisher Copyright:
© 2018 by Thieme Medical Publishers, Inc
PY - 2018
Y1 - 2018
N2 - Human papillomavirus (HPV) infection is responsible for 4.3% of the global cancer burden. Since 2006, current HPV vaccines have reduced the prevalence of the virus in adolescent girls, reduced the prevalence of genital warts, and been proven to reduce the progression of anal intraepithelial neoplasia in men. Herein, we review the epidemiology, virology, and immunology behind the prophylactic HPV vaccines and current recommendations for its use. We also review future immune therapies being trialed for use against HPV-related cancers including anal cancer.Anal cancer , human papillomavirus , anal intraepithelial neoplasia , anal squamous cell cancer.
AB - Human papillomavirus (HPV) infection is responsible for 4.3% of the global cancer burden. Since 2006, current HPV vaccines have reduced the prevalence of the virus in adolescent girls, reduced the prevalence of genital warts, and been proven to reduce the progression of anal intraepithelial neoplasia in men. Herein, we review the epidemiology, virology, and immunology behind the prophylactic HPV vaccines and current recommendations for its use. We also review future immune therapies being trialed for use against HPV-related cancers including anal cancer.Anal cancer , human papillomavirus , anal intraepithelial neoplasia , anal squamous cell cancer.
UR - http://www.scopus.com/inward/record.url?scp=85056130946&partnerID=8YFLogxK
U2 - 10.1055/s-0038-1668101
DO - 10.1055/s-0038-1668101
M3 - Article
C2 - 30397391
AN - SCOPUS:85056130946
SN - 1531-0043
VL - 31
SP - 321
EP - 327
JO - Clinics in Colon and Rectal Surgery
JF - Clinics in Colon and Rectal Surgery
IS - 6
ER -